NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $12.50 -0.64 (-4.87 %) (As of 07/15/2018 04:00 PM ET)Previous Close$12.50Today's Range$12.39 - $13.445052-Week Range$2.69 - $15.80Volume348,349 shsAverage Volume779,372 shsMarket Capitalization$660.27 millionP/E RatioN/ADividend YieldN/ABeta2.35 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts. Receive DRNA News and Ratings via Email Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:DRNA CUSIPN/A Webwww.dicerna.com Phone617-621-8097 Debt Debt-to-Equity RatioN/A Current Ratio6.95 Quick Ratio6.95 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.28 million Price / Sales289.58 Cash FlowN/A Price / CashN/A Book Value$1.96 per share Price / Book6.38 Profitability EPS (Most Recent Fiscal Year)($3.66) Net Income$-60,040,000.00 Net Margins-1,665.11% Return on Equity-123.72% Return on Assets-61.06% Miscellaneous Employees44 Outstanding Shares52,820,000Market Cap$660.27 Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions What is Dicerna Pharmaceuticals' stock symbol? Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA." How were Dicerna Pharmaceuticals' earnings last quarter? Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) issued its quarterly earnings data on Monday, May, 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.57. The biopharmaceutical company earned $1.55 million during the quarter, compared to analysts' expectations of $1.75 million. Dicerna Pharmaceuticals had a negative return on equity of 123.72% and a negative net margin of 1,665.11%. View Dicerna Pharmaceuticals' Earnings History. When is Dicerna Pharmaceuticals' next earnings date? Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Dicerna Pharmaceuticals. What price target have analysts set for DRNA? 7 brokerages have issued 1 year price objectives for Dicerna Pharmaceuticals' stock. Their predictions range from $10.00 to $17.00. On average, they anticipate Dicerna Pharmaceuticals' stock price to reach $14.20 in the next twelve months. This suggests a possible upside of 13.6% from the stock's current price. View Analyst Ratings for Dicerna Pharmaceuticals. What is the consensus analysts' recommendation for Dicerna Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Dicerna Pharmaceuticals? Dicerna Pharmaceuticals saw a increase in short interest in June. As of June 29th, there was short interest totalling 4,192,190 shares, an increase of 144.6% from the June 15th total of 1,713,672 shares. Based on an average daily trading volume, of 1,144,343 shares, the short-interest ratio is currently 3.7 days. Currently, 10.5% of the company's shares are short sold. View Dicerna Pharmaceuticals' Current Options Chain. Who are some of Dicerna Pharmaceuticals' key competitors? Some companies that are related to Dicerna Pharmaceuticals include Clovis Oncology (CLVS), Endo International (ENDP), TESARO (TSRO), Spectrum Pharmaceuticals (SPPI), Akcea Therapeutics (AKCA), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Myokardia (MYOK) and Prestige Brands (PBH). Who are Dicerna Pharmaceuticals' key executives? Dicerna Pharmaceuticals' management team includes the folowing people: Dr. Douglas M. Fambrough III, Co-Founder, Chief Exec. Officer, Pres and Director (Age 49)Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 53)Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 65)Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory BoardProf. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 71) Has Dicerna Pharmaceuticals been receiving favorable news coverage? News headlines about DRNA stock have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a coverage optimism score of 0.07 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 47.53 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. How do I buy shares of Dicerna Pharmaceuticals? Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Dicerna Pharmaceuticals' stock price today? One share of DRNA stock can currently be purchased for approximately $12.50. How big of a company is Dicerna Pharmaceuticals? Dicerna Pharmaceuticals has a market capitalization of $660.27 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe. How can I contact Dicerna Pharmaceuticals? Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected] MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 208 (Vote Outperform)Underperform Votes: 152 (Vote Underperform)Total Votes: 360MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: What does RSI mean?